Jove
Visualize
Contact Us

Related Experiment Videos

Safety considerations for statins.

Chiara Bolego1, Roberta Baetta, Stefano Bellosta

  • 1Department of Pharmacological Sciences, University of Milan, Italy.

Current Opinion in Lipidology
|November 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions.

Atherosclerosis plus·2026
Same author

Corrigendum to "Heated tobacco product aerosol emission compared to cigarette smoke: A scoping review" [Toxicol. Rep. 16 (2026) 102209].

Toxicology reports·2026
Same author

Are we underestimating the benefits of lipid-lowering therapies?

Pharmacological reviews·2026
Same author

Hemostatic Aspects of Interactions Between Anticancer Drugs and Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism.

Seminars in thrombosis and hemostasis·2026
Same author

New frontiers in the treatment of hypercholesterolaemia: oral inhibition of PCSK9.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same author

Fragility Analysis of Cardiovascular Outcomes with Finerenone in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.

European journal of heart failure·2026
Same journal

Editorial introduction.

Current opinion in lipidology·2026
Same journal

Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait.

Current opinion in lipidology·2026
Same journal

Premature atherosclerotic cardiovascular disease in the MENA region: economic impact, barriers to care, and policy recommendations for an escalating crisis.

Current opinion in lipidology·2026
Same journal

The role of metabolic profiling and dietary intervention in the early diagnosis and prevention of atherosclerosis.

Current opinion in lipidology·2026
Same journal

A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients?

Current opinion in lipidology·2026
Same journal

Inflammation and atherosclerotic cardiovascular disease: where do we go from here?

Current opinion in lipidology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Statins are beneficial for high-risk patients but can cause myopathy. Drug interactions significantly increase the risk of statin-induced rhabdomyolysis, though fatal cases remain rare.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Therapeutics

Background:

  • Hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins) are crucial for managing coronary heart disease risk.
  • While generally safe, statins exhibit varying properties influencing long-term safety.
  • Hepatotoxicity and myopathy are key adverse effects of statin therapy.

Purpose of the Study:

  • To review long-term adverse effects of statins, focusing on hepatotoxicity and myopathy.
  • To analyze drug-drug interactions between statins and commonly co-prescribed medications.
  • To assess the impact of these interactions on statin safety profiles.

Main Methods:

  • Literature review of adverse events associated with statin use.
  • Analysis of case reports and regulatory data regarding statin-induced myopathy and rhabdomyolysis.

Related Experiment Videos

  • Examination of pharmacokinetic and pharmacodynamic interactions between statins and other drugs.

    • Main Results:

    • The withdrawal of cerivastatin highlighted risks, with drug interactions implicated in ~60% of rhabdomyolysis cases.
    • Fatal rhabdomyolysis associated with statin use is rare, with low reporting rates across most statins.
    • Hepatotoxicity and myopathy remain important considerations in long-term statin therapy.

    Conclusions:

    • Statins are recommended as first-line treatment due to significant cardiovascular benefits outweighing myopathy risks.
    • Clinicians must remain vigilant for adverse effects, especially in patients on multiple long-term medications.
    • Awareness of potential drug interactions is critical for safe statin prescribing.